19-382 - Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Status: openPhase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Treatment for Lung Cancer
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Sponsors
This trial is sponsored by ECOG-ACRIN.Principle Investigator
Providers Associated With This Trial
Sub Investigators
![Daniel Cameron]()
View ProfileDaniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology![Persing brian]()
View ProfileBrian E. Persing, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.